New hope as Alzheimer’s drug slows memory decline in phase 3 trial
- Dr. Stephen Thomas
- Nov 1, 2022
- 1 min read
Updated: Nov 18, 2022
28 September 2022
It’s news we’ve all been waiting for. Today, the pharmaceutical company Eisai announced that their drug, lecanemab, has shown small but clear benefits for people with early Alzheimer’s in a rigorous, well-conducted phase 3 trial.
Comments